Market capitalization | $2.00b |
Enterprise Value | $2.03b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.61 |
P/S ratio (TTM) P/S ratio | 6.50 |
P/B ratio (TTM) P/B ratio | 8.59 |
Revenue growth (TTM) Revenue growth | 112.14% |
Revenue (TTM) Revenue | $307.03m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a Mirum Pharmaceuticals Inc forecast:
11 Analysts have issued a Mirum Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 307 307 |
112%
112%
|
|
Gross Profit | 225 225 |
91%
91%
|
|
EBITDA | -70 -70 |
32%
32%
|
EBIT (Operating Income) EBIT | -93 -93 |
16%
16%
|
Net Profit | -97 -97 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
Head office | United States |
CEO | Christopher Peetz |
Employees | 264 |
Founded | 2018 |
Website | www.mirumpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.